Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide
- PMID: 9039122
- DOI: 10.1161/01.hyp.29.1.320
Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide
Abstract
Nitric oxide (NO) inhibits a variety of heme-containing enzymes, including NO synthase and cytochrome P4501A1 and 2B1. The present study examined whether NO inhibits the production of 20-hydroxyeicosatetraenoic acid (20-HETE) by cytochrome P4504A enzymes and whether blockade of the production of this substance contributes to the vascular effects of NO. Sodium nitroprusside (SNP; 10(-5), 10(-4), and 10(-3) mol/L) reduced the production of 20-HETE by renal microsomes incubated with arachidonic acid to 71 +/- 5%, 29 +/- 4%, and 4 +/- 2% of control, respectively (n = 5). Similar results were obtained with the use of 1-propanamine, 3-(2-hydroxy-2-nitroso-1-propylhydrazino) (n = 3). To determine whether inhibition of 20-HETE contributes to the vasodilatory effects of NO, the effects of dibromo-dodecenyl-methylsulfimide (DDMS), a selective inhibitor of the formation of 20-HETE, on the response to SNP (10(-7) to 10(-3) mol/L) were examined in rat renal arterioles preconstricted with phenylephrine (n = 5). SNP increased vascular diameter in a concentration-dependent manner to 82 +/- 4% of control. After DDMS (25 mumol/L), SNP (10(-3) mol/L) increased vascular diameter by only 17 +/- 3%. The effects of DDMS on the mean arterial pressure (MAP) and renal blood flow (RBF) responses to infusion of an NO donor and a synthase inhibitor were also examined in thiobutabarbital-anesthetized, Sprague-Dawley rats. Infusion of MAHMA NONOate at 1, 3, 5, and 10 nmol/min reduced MAP by 16 +/- 2, 30 +/- 3, 40 +/- 5, and 48 +/- 5 mm Hg and lowered renal vascular resistance (RVR) by 15 +/- 3%, 26 +/- 2%, 30 +/- 3%, and 34 +/- 4% of control. After DDMS (10 mg/kg, n = 7 rats), the MAP and RVR responses to 1-hexamine, 6-(2-hydroxy-1-methyl-2-nitrohydrazino)N-methyl (MAHMA NONOate) averaged only 20% of those seen during control. In other experiments, MAP increased by 32 +/- 4% and RBF fell to 56 +/- 5% of control after administration of N-nitro-L-arginine (L-NArg) (10 mg/kg IV). After DDMS (10 mg/kg, n = 7 rats), MAP increased by only 19 +/- 4% and RBF fell by only 7 +/- 4% after L-NArg. These results indicate that NO inhibits cytochrome P4504A enzymes and that inhibition of the production of 20-HETE contributes to the vasodilatory effects of NO.
Similar articles
-
Cytochrome P-450 metabolites in renal circulation and excretion--interaction with the nitric oxide (NO) system.J Physiol Pharmacol. 2008 Dec;59 Suppl 9:137-49. J Physiol Pharmacol. 2008. PMID: 19261977 Review.
-
Renal 20-HETE inhibition attenuates changes in renal hemodynamics induced by L-NAME treatment in pregnant rats.Am J Physiol Renal Physiol. 2005 Nov;289(5):F1116-22. doi: 10.1152/ajprenal.00149.2005. Epub 2005 Jul 5. Am J Physiol Renal Physiol. 2005. PMID: 15998843
-
Cytochrome P450 metabolites of arachidonic acid in the control of renal function.Curr Opin Nephrol Hypertens. 2001 Jan;10(1):81-7. doi: 10.1097/00041552-200101000-00013. Curr Opin Nephrol Hypertens. 2001. PMID: 11195057 Review.
-
Contribution of 20-HETE to vasodilator actions of nitric oxide in the cerebral microcirculation.Stroke. 1999 Dec;30(12):2727-34; discussion 2734. doi: 10.1161/01.str.30.12.2727. Stroke. 1999. PMID: 10583004
-
Contribution of 20-HETE to the vasodilator actions of nitric oxide in renal arteries.Am J Physiol. 1998 Sep;275(3):F370-8. doi: 10.1152/ajprenal.1998.275.3.F370. Am J Physiol. 1998. PMID: 9729509
Cited by
-
G Protein-Coupled Receptor 75 (GPR75) As a Novel Molecule for Targeted Therapy of Cancer and Metabolic Syndrome.Asian Pac J Cancer Prev. 2023 May 1;24(5):1817-1825. doi: 10.31557/APJCP.2023.24.5.1817. Asian Pac J Cancer Prev. 2023. PMID: 37247305 Free PMC article. Review.
-
20-Hydroxyeicosatetraenoic acid (20-HETE): Bioactions, receptors, vascular function, cardiometabolic disease and beyond.Adv Pharmacol. 2023;97:229-255. doi: 10.1016/bs.apha.2023.01.002. Epub 2023 Feb 24. Adv Pharmacol. 2023. PMID: 37236760 Free PMC article.
-
Candidate neuroinflammatory markers of cerebral autoregulation dysfunction in human acute brain injury.J Cereb Blood Flow Metab. 2023 Aug;43(8):1237-1253. doi: 10.1177/0271678X231171991. Epub 2023 May 3. J Cereb Blood Flow Metab. 2023. PMID: 37132274 Free PMC article. Review.
-
Epoxyeicosatrienoic Acid Analog and 20-HETE Antagonist Combination Prevent Hypertension Development in Spontaneously Hypertensive Rats.Front Pharmacol. 2022 Jan 17;12:798642. doi: 10.3389/fphar.2021.798642. eCollection 2021. Front Pharmacol. 2022. PMID: 35111064 Free PMC article.
-
Increased 20-HETE Signaling Suppresses Capillary Neurovascular Coupling After Ischemic Stroke in Regions Beyond the Infarct.Front Cell Neurosci. 2021 Nov 8;15:762843. doi: 10.3389/fncel.2021.762843. eCollection 2021. Front Cell Neurosci. 2021. PMID: 34819839 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources